Skip to main content
Clinical Trials/NCT05802498
NCT05802498
Completed
Not Applicable

IR3MA Parkinson Cyclone in Life: Innovation, R3 Rehabilitation - Resonance - RTD Fluxgate Sensor, Multidisciplinary Approach

IRCCS Centro Neurolesi "Bonino-Pulejo"1 site in 1 country24 target enrollmentJuly 21, 2020

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Parkinson Disease
Sponsor
IRCCS Centro Neurolesi "Bonino-Pulejo"
Enrollment
24
Locations
1
Primary Endpoint
Berg Balance Scale (BBS)
Status
Completed
Last Updated
3 years ago

Overview

Brief Summary

Comparison of two rehabilitation protocols in patients with Parkinson's disease and, therefore, identification of innovative rehabilitation protocols of proven and validated efficacy, through which it is possible to achieve:

  • Improved joint function and gait pattern
  • Reduction of the risk of falling or reduction of energy expenditure during physiological gait

Evaluation of the increase in maximal effort tolerance

· Improved cognitive performances

Evaluation of the impact on the quality of life of the patient and family members

Identification of morpho-functional markers predictive of clinical and rehabilitative out-come through neuroimaging study.

Detailed Description

rehabilitation protocols in patients with Parkinson's disease and, therefore, identification of innovative rehabilitation protocols of proven and validated efficacy, through which it is possible to achieve: Improved joint function and gait pattern Reduction of the risk of falling or reduction of energy expenditure during physiological gait Evaluation of the increase in maximal effort tolerance · Improved cognitive performances Evaluation of the impact on the quality of life of the patient and family members Identification of morpho-functional markers predictive of clinical and rehabilitative out-come through neuroimaging study.

Registry
clinicaltrials.gov
Start Date
July 21, 2020
End Date
January 20, 2023
Last Updated
3 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Hoehn \& Yahr between 2.0 and 3.0;
  • No need for a walking aid;
  • Mini-Mental State Examination (MMSE) score \>24;
  • Effective dopaminergic pharmacological control;
  • Absence of other relevant neurological comorbidities;
  • Absence of postural deformities (and/or Pisa syndrome);
  • Absence of severe cardiological pathologies (exertional angina, severe decompensation).
  • Ability to travel to the rehabilitation treatment site independently or with support

Exclusion Criteria

  • presence of Deep Brain Stimulation (DBS);
  • presence of severe heart and/or lung disease;
  • presence of therapeutic regimen in the definition phase;
  • impaired joint and/or motor function to follow a proposed rehabilitation treatment programme
  • contraindications to performing MRI scans
  • undergoing rehabilitation therapy in the 3 months preceding enrolment.

Outcomes

Primary Outcomes

Berg Balance Scale (BBS)

Time Frame: 8 weeks

The Berg Balance Scale is a scale for assessing balance and the risk of falling

Study Sites (1)

Loading locations...

Similar Trials